Kala Bio Return on Equity

Kala Bio (KALA) currently reports a ROE of -93.53%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Kala Bio's ROE history and peer comparisons.

Kala Bio's ROE of -93.53% is lower than the Healthcare sector average of 20.86%. That is roughly 548.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Kala Bio's current -93.53% should be judged against Healthcare norms (sector average: 20.86%) and against KALA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -93.53%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Kala Bio, and consider following KALA for alerts when major investors trade the stock.

Kala Bio is classified in the Healthcare sector. On ROE, it currently shows -93.53% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KALA with unrelated industries.